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Introduction
Patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lym-
phoma (ALCL) often present with B symptoms or a macrophage activation syn-
drome indicating an inflammatory or immune reaction.1 In addition, ALK-positive
ALCL elicits a specific host immune response, as indicated by the production of anti-
ALK-autoantibodies,2 and a cellular immune response against ALK.3-6 In some
aspects, the immune response in ALCL is comparable to that occurring in patients
with Hodgkin lymphoma, in whom elevated serum cytokine levels have been
described at the time of diagnosis.7,8
Elevated levels of serum cytokines as immune mediators, such as interleukin (IL)-
6, IL-8, IL-10, IL-17a, and IL-22, have also been shown in small series of ALK-positive
ALCL patients.9,10 In vitro production of IL-6, IL-8 and interferon (IFN)-γ by an ALK-
positive ALCL cell line HSC-M1 has been reported.11 Soluble CD30 (sCD30) and the
soluble IL-2 receptor (sIL-2R) can be shed from ALCL cells and their levels were
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found to be elevated in seven ALK-positive ALCL patients.12
sCD30 levels correlated with an inferior survival in a series
of adult ALCL patients with unknown ALK-status.13,14 IL-9
has been described as part of an autocrine signaling path-
way including JAK3 with a possible role in the pathogenesis
of ALK-positive ALCL.15 IL-22 expressed in three ALCL cell
lines contributes to STAT3 activation and tumorigenicity of
ALK-positive ALCL.16
While above-mentioned reports highlight ALCL as a
cytokine-active lymphoma with hints towards an ALCL-
type cytokine signature, the type and pattern of cytokine
expression among ALK-positive ALCL patients has not
been analyzed systematically. Pretreatment serum cytokine
levels may reflect the biological activity of the tumor as well
as host immune characteristics. Correlations of initial
cytokine concentrations and patterns with patients’ charac-
teristics, antibody titers against ALK as a surrogate measure
of an autologous immune response against ALK, as well as
outcomes might allow the definition of cytokine profiles
that are associated with disease activity, tumor burden and
the patients’ specific immune response. 
We, therefore, investigated whether pretreatment
cytokine concentrations in patients with ALK-positive
ALCL correlate with biological and clinical characteristics
and ALK-antibody titers in a uniformly treated, large cohort
of 119 children and adolescents with ALK-positive ALCL.
Methods
Eligibility
NPM-ALK-positive ALCL patients treated in the Berlin-
Frankfurt-Muenster group study NHL-BFM95 or German patients
enrolled in the European intergroup trial ALCL99 between August
1998 and December 2008 were potentially eligible for inclusion in
this study after giving written informed consent to participation.
Both studies were approved by the institutional ethics committee
of the primary investigator of the NHL-BFM study group (AR).
Patients with completely resected stage I disease were excluded
because their treatment was different.
Patients were included if there were pretreatment serum or plas-
ma samples available and had detectable anti-ALK antibody titer
levels. Eligibility was confirmed by demonstration of NPM-ALK
positivity of the tumor either by NPM-ALK polymerase chain
reaction, two-color fluorescence in situ hybridization for t(2;5) or
nuclear and cytoplasmic staining for ALK.
Patients
The inclusion criteria were fulfilled by 119 patients. Staging pro-
cedures included bone marrow aspiration cytology and a spinal
tap. Bone marrow involvement was defined by cytologically
detectable ALCL cells, irrespective of their number. The patients’
treatment consisted of a cytoreductive prephase followed by six
chemotherapy courses, as described elsewhere.17
As control, serum or plasma samples from 15 of those patients
in remission without concurrent infection taken before the start of
the sixth chemotherapy course were analyzed. 
In addition, serum samples taken at the time of diagnosis from
11 age-matched patients with Burkitt lymphoma from risk groups
R1 and R2 (stage I – III, lactate dehydrogenase below 500 U/L)
included in the B-NHL BFM 04 study served as a second control
group.
Methods and the patients’ results regarding ALK-antibody titers
and minimal disseminated disease at diagnosis were described and
published previously.18-20
Measurement of cytokine levels
Blood samples were centrifuged and supernatants were
immediately frozen and stored at -80°C until analysis. Samples
were assessed for the levels of following soluble mediators: IL-
1β, IL-2, sIL-2R, IL-4, IL-5, IL-6, IL-8, IL-9, IL-10, IL-12p70, IL-
13, IL-17a, IL-22, IL-23, tumor necrosis factor-α (TNF-α), IFN-
γ, monokine induced by γ-interferon (MIG), interferon γ-
induced protein 10 (IP-10), hepatocyte growth factor (HGF),
vascular endothelial growth factor (VEGF), monocyte
chemoattractant protein-1 (MCP-1), macrophage inflammatory
protein (MIP)-1α, MIP-1β, granulocyte colony-stimulating fac-
tor (G-CSF) and soluble CD30 (sCD30). The measurements
were performed using  FlowCytomix kits (eBioscience,
Frankfurt, Germany) according to the manufacturer’s instruc-
tions. Samples were processed on a FACS Calibur (BD,
Heidelberg, Germany) and data were analyzed using the
FlowCytomix Software (version 2.4, eBioscience, Frankfurt,
Germany).
Statistical methods
Statistical calculations were performed using the R statistical
package (R Foundation for Statistical Computing, Vienna,
Austria).
Cytokine levels are reported as median values and were com-
pared between different groups according to diagnosis, clinical
and biological characteristics using Mann-Whitney U and
Kruskal-Wallis tests. The level of statistical significance was
0.05. Event-free survival was defined as the time from diagnosis
to relapse, secondary tumor or death from any cause. Estimates
of overall and event-free survival were performed using the
Kaplan-Meier method. Differences between groups were com-
pared by log-rank test. A multivariate analysis was performed
using the proportional hazards method described by Cox on
cytokines showing significant differences in univariate analysis
and known risk factors20 with forward selection keeping only
significant variables (P<0.05) in the model.
Results
Patients’ characteristics
The median age of the 119 ALCL patients at diagnosis
was 12.0 years (range, 0.3 – 17.8) and 58% (69 patients)
were male. The median follow-up was 6.6 years. The 3-
year event-free survival rate of the 119 ALCL patients
was 66.4 ± 4.3% and their 3-year overall survival rate was
86.5 ± 3.1%. Detailed clinical data of the patients and
controls are shown in Online Supplementary Table S1.
Pretreatment cytokine levels in patients with 
anaplastic lymphoma kinase-positive anaplastic 
large cell lymphoma
Concentrations of IL-9, IL-10, IL-17a, HGF, sIL-2R, and
sCD30 were significantly higher in ALCL patients at the
time of diagnosis than in the patients in either control
group (patients with B-cell non-Hodgkin lymphoma and
ALCL patients in remission) (Figure 1). 
The median concentrations of all cytokines are shown
in Online Supplementary Table S2. In 28 ALCL patients,
measurements of sIL-2R were above the upper detection
limit of 221 869.99 pg/mL. For the analyses, these sam-
ples were attributed a value of 221 869.99 pg/mL. IP-10
could not be measured in one patient.
Correlations between cytokine concentrations are
shown in Online Supplementary Table S3. 
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Correlation of cytokine levels with clinical and 
laboratory characteristics
Correlations between cytokine concentrations and vari-
ous clinical and laboratory characteristics are summarized
in Table 1.
Age and sex
There was no significant difference in the median cytokine
concentrations between girls and boys. Concentrations of IL-
17a (P=0.018) and MIP-1α (214.4 pg/mL versus 106.5 pg/mL,
P=0.02) were higher in patients aged 0 – 9 years (41/119) than
in patients over 9 years old. Levels of IL-2 (P=0.02) and IL-8
(32.1 pg/mL versus 79.3 pg/mL, P=0.038) were higher in
patients older than 9 years (78/119).
Stage and organ involvement
Patients with Murphy stage III or IV (88/116) had signif-
icantly higher concentrations of IL-6 (P=0.002), IL-10
(P=0.02), IFN-γ (P=0.013), IP-10 (P=0.009), MIG (P=0.001),
VEGF (P=0.048), HGF (P=0.017), sCD30 (P<0.001), and
sIL-2R (P<0.001) compared to patients with a lower stage
(Online Supplementary Figure S1).
Bone marrow infiltration, defined as blasts detectable
in bone marrow smears, was detected in 16 of the 119
(13.4%) ALCL patients. These patients had significantly
higher concentrations of IL-6 (30.1 pg/mL versus 0 pg/mL,
P=0.011), IL-10 (281.2 pg/mL versus 0 pg/mL, P=0.003),
IL-13 (7/16 versus 18/103 elevated, P=0.013), TNF-α (8/16
versus 20/103 elevated, P=0.005), IFN-γ (8.2 pg/mL versus
Blood cytokine concentrations in ALK-positive ALCL
haematologica | 2018; 103(3) 479
Figure 1. Cytokine levels in patients with anaplastic lymphoma kinase-positive anaplastic large cell lymphoma and controls. Logarithmic representation of cytokine
levels in pg/mL for 119 ALCL patients at the time of diagnosis, 15 ALCL patients in remission and 11 patients with B-cell non-Hodgkin lymphoma (B-NHL).
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0 pg/mL, P=0.002), IP-10 (343.9 pg/mL versus 118.3
pg/mL, P=0.002), MIG (441.0 pg/mL versus 276.4 pg/mL,
P=0.006), and sIL-2R (190649.2 pg/mL versus 82290.3
pg/mL, P=0.01) compared to patients without bone mar-
row involvement.
The central nervous system was involved in two of the
116 patients who had a lumbar puncture. Both patients
had high concentrations of IL-6 (170.9 pg/mL, 513.5
pg/mL) and IL-17a (2623.3 pg/mL, 1468.3 pg/mL).
Correlations of cytokine concentrations with other
organ involvement (skin, mediastinum, liver, lung and
spleen) are shown in Online Supplementary Table S4.
Patients in a poorer general condition (24/119) at the
time of diagnosis (4 or 5 on a subjective scale from 1 to 5)
had significantly higher concentrations of IL-1β (P=0.013),
IL-6 (P<0.001), IL-10 (P<0.001), IL-12p70 (P=0.024), IL-17a
(P<0.001), HGF (P<0.001), sIL-2R (P<0.001), VEGF
(P=0.006), IFN-γ (P=0.039), and IP-10 (P=0.025) (Online
Supplementary Figure S2).
B symptoms, leukocytosis, C-reactive protein, and lactate 
dehydrogenase levels
In comparison to patients without B symptoms,
patients with B symptoms (63/119) had significantly high-
er concentrations of IL-6 (P=0.001), IL-10 (P<0.001), IL
12p70 (P=0.024), IFN-γ (P=0.04), MIG (P=0.046), HGF
(P=0.002), sIL-2R (P<0.001), sCD30 (P=0.002), and IP-10
(P=0.008), and lower median concentrations of G-CSF
(P=0.035). Likewise, patients with CRP values above 4
mg/L (64/119) had significantly higher concentrations of
sIL-2R (P<0.001), IL-6 (P<0.001), IL-10 (P=0.044), IL-17a
(P=0.002), HGF (P=0.006), and sCD30 (P<0.001) than
patients with a lower CRP.
Patients with lactate dehydrogenase values above 240
U/L (57/119) had significantly higher concentrations levels
of sIL-2R (P<0.001), IP-10 (P=0.003), MIG (P<0.001), and
sCD30 (P=0.008). Patients with leukocytosis (white blood
cells: >10 x 109/L, 47/119) had significantly higher concen-
trations of IL-1β (P=0.043), IL-17a (P<0.001), IL-6 (P=0.01),
and HGF (P=0.003).
Histological subtype
Histological subtype was analyzed in 87 ALCL patients.
The 37 patients with non-common histological subtype
had significantly higher concentrations of IL-6 (13.2
pg/mL versus 0 pg/mL, P=0.047) and IL-17a (P=0.018) as
compared to patients with a common histology.
Correlations of cytokine levels with biological 
characteristics
Minimal disseminated disease 
Minimal disseminated disease, defined as a positive
polymerase chain reaction for NPM-ALK transcripts in
bone marrow or peripheral blood, was detected at diagno-
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Figure 2. Cytokine levels correlated with minimal disseminated disease.
Logarithmic representation of cytokine levels in pg/mL of ALK-positive ALCL
patients at time of diagnosis according to the detection of minimal disseminat-
ed disease (positive n=55, negative n=46). G-CSF levels were higher in patients
without minimal disseminated disease. Only cytokines for which significant dif-
ferences were found are shown.
sis in 55 of 101 evaluable patients. The presence of mini-
mal disseminated disease, an independent prognostic fac-
tor in ALK-positive ALCL, was associated with elevated
concentrations of IL-6 (20.7 pg/mL versus 0 pg/mL,
P=0.001), IL-10 (37.4 pg/mL versus 0 pg/mL, P<0.001), IL-
17a (P=0.031), MCP-1 (588.8 pg/mL versus 383.8 pg/mL,
P=0.008), HGF (3877.2 pg/mL versus 2101.1 pg/mL,
P=0.002), IP-10 (272.94 pg/mL versus 108.3 pg/mL,
P<0.001), sCD30 (137 449.9 pg/mL versus 51 781.1 pg/mL,
P=0.001), and sIL-2R (159 428.4 pg/mL versus 30 087.6
pg/mL, P<0.001) (Figure 2). G-CSF (48.1 pg/mL versus 0
pg/mL, P=0.041) and MIP-1α concentrations (214.2 pg/mL
versus 106.6 pg/mL, P=0.042) were significantly higher in
patients without minimal disseminated disease.
Using quantitative polymerase chain reaction, 29 of 90
patients were found to have a normalized copy number
>10, where the number of copies of NPM-ALK is  normal-
ized to 10 000 copies of ABL. Concentrations of sIL-2R
(P<0.001), IL-6 (P=0.004), IL-10 (P<0.001), IFN-γ (P<0.001),
MIG (P=0.041) and IP-10 (P=0.003) were higher among
these patients than among patients with lower normal-
ized copy numbers.
Anti-anaplastic lymphoma kinase-antibody titers
Anti-ALK antibody titers inversely correlate with the
risk of relapse and may serve as a surrogate for the
strength of the ALK-specific immune response.19,20 The
patients were grouped according to the strength of the
antibody titer into those with low (≤1/750), intermediate
(>1/750 – <1/60750) and high (≥1/60750) titers. There
were 34, 53, and 32 patients in the low, intermediate and
high titer groups, respectively.
Patients with a low titer had significantly higher median
concentrations of sIL-2R (P=0.013), IL-6 (P<0.001), IFN-γ
(P=0.022), and IP-10 (P=0.021), but lower concentrations
of IL-23 (P=0.008) compared to patients with an interme-
diate or high titer (Figure 3).
Correlation of cytokine levels with outcomes 
In univariate analysis, patients with concentrations
above the median of IL-6, IL-10, IL-17a, IFN-γ, MCP-1,
HGF, IP-10 and sIL-2R had a significantly lower 3-year
event-free survival rate compared to patients with levels
below the median (Table 2). The greatest difference in
event-free survival rates was found between patients with
IL-6 concentrations above the detection threshold and
patients with no detectable IL-6 [event-free survival:
85.7% (95% confidence interval: 77.5 - 94.8) versus 44.6%
(95% confidence interval: 33.4 - 59.8), P(log-rank)<0.001].
In a stepwise Cox regression analysis, including known
risk factors and all cytokines for which findings were sig-
nificant in the univariate analysis, only IL-6 retained an
independent prognostic value with a hazard ratio of 2.9 ±
0.4 (Table 2).
F. Knörr et al.
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Figure 3. Cytokine levels correlated with anti-
anaplastic lymphoma kinase antibody titer.
Median cytokine levels are shown for patients
with low (≤1/750, n=34), intermediate
(>1/750 – <1/60750, n=53), and high
(≥1/60750, n=32) anti-ALK antibody titers.
Logarithmic representation, values in pg/mL.
Only cytokines for which significant differ-
ences were found are shown.
Discussion
The aim of this study was to describe pretreatment
serum cytokine concentrations and correlate them with
clinical and biological characteristics among pediatric
patients with NPM-ALK-positive ALCL. 
Although blood was collected at 51 different trial sites,
serum or plasma was used depending on availability, the
time from blood collection to freezing varied by several
hours and the storage period differed considerably, the
correlations found between cytokines and clinical charac-
teristics such as IL-6 and the patients’ general condition
(Table 1) are indicative of reliable measurements.
Elevated pretreatment cytokine levels in patients with
ALCL compared to either post-treatment samples or other
non-Hodgkin-lymphoma patients have been reported in
two series of patients. Savan et al. found higher levels of
IL-22 and IL-8 in nine of 11 untreated ALCL patients com-
pared to post-treatment controls.9 Mellgren et al. recorded
higher levels of IL-6, IL-10, MIP-1α, and sIL-2R in six pedi-
atric ALCL patients at time of diagnosis compared to the
levels in children with other non-Hodgkin lymphoma.10
Our systematic analysis of serum cytokine levels con-
firmed and extended these findings in a large group of
children with untreated NPM-ALK-positive ALCL. IL-9,
IL-10, IL-17a, HGF, sIL-2R, and sCD30 levels form a kind
Blood cytokine concentrations in ALK-positive ALCL
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Table 2. Cytokines in univariate and multivariate analyses.
                                                                                         Univariate                    Multivariate
                                                     Patients               Events                      HR                              P                                    HR                               P
Minimal disseminated disease              101                                                         6.0 ± 0.4                          <0.001                                  6.6 ± 0.5                            < 0.001
Positive                                                       55                            31                                                                                                                                                                 
Negative                                                     46                             6                                                                                                                                                                   
AntiALK antibody titer                              119                                                         3.7 ± 0.3                          < 0.001                                 3.6 ± 0.4                            < 0.001
≤ 1/750                                                        34                            21                                                                                                                                                                 
> 1/750                                                        85                            21                                                                                                                                                                 
Clinical risk (HR)                                      119                                                         6.5 ± 0.5                          < 0.001                                 4.5  ± 0.5                              0.005
Standard risk                                             42                             5                                                                                                                                                                   
High risk                                                     77                            37                                                                                                                                                                 
B symptoms                                                119                                                         2.3 ± 0.3                             0.01                                                                                     
Positive                                                       63                            29                                                                                                                                                                 
Negative                                                     56                            13                                                                                                                                                                 
Histology                                                      87                                                          2.2 ± 0.4                            0.038                                                                                    
Non-common                                            37                            17                                                                                                                                                               
Common                                                    50                            13                                                                                                                                                               
sIL-2R                                                           119                                                         2.7 ± 0.3                            0.002                                                                                    
> median                                                   59                            28                                                                                                                                                                 
≤ median                                                    60                            14                                                                                                                                                                 
IL-6                                                               119                                                         5.0 ± 0.4                          < 0.001                                 2.9 ± 0.4                              0.007
> 0 pg/mL                                                  56                            32                                                                                                                                                                 
= 0 pg/mL                                                  63                            10                                                                                                                                                                 
IL-10                                                             119                                                         2.9 ± 0.3                            0.001                                                                                    
> 0 pg/mL                                                  53                            27                                                                                                                                                                 
= 0 pg/mL                                                  66                            15                                                                                                                                                                 
IL-17a                                                           119                                                         2.5 ± 0.3                            0.004                                                                                    
> 0 pg/mL                                                  43                            22                                                                                                                                                                 
= 0 pg/mL                                                  76                            20                                                                                                                                                                 
IFN-γ                                                            119                                                         3.5 ± 0.3                          < 0.001                                                                                  
> 0 pg/mL                                                  29                            18                                                                                                                                                                 
= 0 pg/mL                                                  90                            24                                                                                                                                                                 
IP-10                                                             118                                                         2.3 ± 0.3                            0.008                                                                                    
> median                                                   59                            27                                                                                                                                                                 
≤ median                                                    59                            15                                                                                                                                                                 
MCP1                                                            119                                                         2.6 ± 0.3                            0.003                                                                                    
> median                                                   59                            29                                                                                                                                                                 
≤ median                                                    60                            13                                                                                                                                                                 
HGF                                                              119                                                         2.5 ± 0.3                            0.004                                                                                    
> median                                                   59                            28                                                                                                                                                                 
≤ median                                                    60                            14                                                                                                                                                                   
sCD30                                                           119                                                       2.0 ± 0.3                            0.028                                                                                      
> median                                                   60                            27                                                                                                                                                                   
≤ median                                                    59                            15                                                                                                                                                               
Stepwise regression was used to test whether cytokines have additional prognostic value having taken into account the known risk factors minimal disseminated disease, anti-
ALK-antibody titer and clinical risk group.37 HR, hazard ratio.
of cytokine-signature for ALK-positive ALCL when com-
pared with those of both remission samples and samples
from age-matched children with low-stage B-cell non-
Hodgkin lymphoma as separate controls. 
The concentrations of sIL-2R and sCD30 were expect-
edly higher in ALCL patients than in controls since ALCL
cells, by definition, express CD30 and show strong stain-
ing for CD25, the α-subunit of the IL-2 receptor.12-14,21 Both
molecules can be shed by the tumor cells.12,22 The detection
of IL-9 would be in accordance with the previously
described autocrine IL-9/JAK3 signaling in ALCL.15 ALCL
cells have been described to resemble a Th17 phenotype
and to produce IL-17.9,23 Cumulatively, these data suggest
that these elevated serum cytokines might be produced by
the lymphoma. 
Within the cohort of patients with ALK-positive ALCL,
high levels of IL-6, IFN-γ, IP-10, and sIL-2R correlated
with high stage, initial poor general condition, minimal
disseminated disease, low ALK-antibody titers, and
lower event-free survival at 3 years. The concentrations
of sIL-2R and IL-6 correlate with the extent of disease,
relapse risk and survival in different tumor types includ-
ing Hodgkin lymphoma and peripheral T-cell
lymphoma.24-27 The levels of sIL-2R, sCD30 and IL-6 have
been described as independent prognostic markers in
both Hodgkin lymphoma patients and patients with
peripheral T-cell lymphoma.8,27,28 Several strong inde-
pendent biological prognostic parameters are available in
patients with ALK-positive ALCL.29 It is not, therefore,
unexpected that only IL-6 retained an independent prog-
nostic value for event-free survival in our cohort of ALK-
positive ALCL patients in a multivariate analysis includ-
ing the established risk factors, minimal disseminated
disease and anti-ALK antibody titers.18-20
sIL-2R was described as a marker of disease activity in a
cohort of nine ALK-negative and ALK-positive ALCL
patients evaluated at different time points.12 As for sIL-2R,
higher levels of sCD30 were associated with higher stage,
presence of minimal disseminated disease and other clini-
cal characteristics in our cohort. These findings support a
role of sCD30 and sIL-2R as markers of tumor burden.25
The cumulative observations that IL-23 levels correlated
directly with the anti-ALK antibody titers in our study and
that this cytokine has been shown to be produced by acti-
vated dendritic cells,30 is involved in Th17 effector func-
tions31 and has a role in autoimmunity32 might suggest that
IL-23 could support the production of autoantibodies.
Elevated concentrations of IL-10 were correlated with
minimal disseminated disease positivity, disease stage and
significantly lower event-free survival at 3 years in uni-
variate analyses and could hint toward an immune eva-
sion of the tumor. ALK-positive ALCL express PD-L1,33
involved in suppression of the immune response, and  IL-
10-secretion in ALK-positive ALCL is induced via STAT3
signaling.34 Elevated concentrations of IL-10 may reflect
immune evasion of the tumor and suppression of cytotox-
ic T-cell functions.
We also investigated whether a Th-subset-specific
serum cytokine pattern could be identified in ALCL
patients. Although some patients showed a pattern of ele-
vated IFN-γ, IP-10 and MIG (these latter two both pro-
duced upon stimulation with IFN-γ35) and levels of IL-17
and IL-23 might hint towards the activation of Th17 cells,
the majority of ALCL patients did not show a conclusive
pattern. The concept of a certain Th response linked to a
disease has been questioned by the discovery of a plethora
of newly described subsets and the plasticity of those cell
types.36 In addition, a multitude of host factors, tumor dis-
semination and individual tumor characteristics could
influence the cytokine expression pattern.
In summary, our findings suggest that expression of IL-
9, IL-10, IL-17a, HGF, sIL-2R, and sCD30 form a cytokine
signature typical of ALK-positive ALCL. The levels of IL-
6, IFN-γ, IP-10, and sIL-2R correlated with lymphoma dis-
semination, other poor prognostic factors and the risk of
relapse among pediatric patients with ALK-positive ALCL.
Our data underline the role of immune mediators in
explaining part of the typical clinical presentation of ALCL
patients with B symptoms and further signs of systemic
inflammation. IL-6, as a classical cytokine marker of
inflammation, was also an independent prognostic param-
eter. More work is needed to elucidate the role of the cel-
lular immune response to ALK-positive ALCL and to
understand the role of mediators in the tumor microenvi-
ronment in patients.
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